1 / 29

HuBio 543 September 25, 2007

HuBio 543 September 25, 2007. Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Introduction to the Sympathetic Nervous System. Catecholamines. NH. HO. +. 2. HO. Catechol Plus Amine. OH. H. OH. H. NH. HO. HO. C. C. C. C. NH. CH. 2. 3. HO. HO. H.

belden
Télécharger la présentation

HuBio 543 September 25, 2007

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HuBio 543September 25, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Introduction to the Sympathetic Nervous System

  2. Catecholamines NH HO + 2 HO Catechol Plus Amine OH H OH H NH HO HO C C C C NH CH 2 3 HO HO H H H H Epinephrine Norepinephrine H H H OH CH 3 NH NH HO C C C C CH HO 2 CH HO HO H 3 H H H Dopamine Isoproterenol

  3. Adrenergic Innervation of Vasculature

  4. ADRENERGIC TRANSMISSION Tyrosine TH Tyrosine DOPA DDC Dopamine MAO DA ++ Ca ++ Ca DßH NE NE NE Transp. NE AdR COMT

  5. ++ Ca ++ Ca SYNTHESIS OF EPINEPHRINE IN THE ADRENAL MEDULLA TH Tyrosine DOPA DDC Dopamine PMNT DA NE EPI DßH NE EPI EPI

  6. CAT ACh + CoA Ch + AcCoA NE NE NE ACh ACh ACh TERMINATION OF SYNAPTIC TRANSMISSION NE ACh Re-Up NE ACh Ch +Ac AdR AChE AChR

  7. Metabolism of Catecholamines OH H OH O MAO NH C C HO 2 HO C C OH HO HO H H H H 3,4- Dihydroxymandelic acid Norepinephrine OH H OH H COMT H3CO NH NH HO C C C C 2 2 HO HO H H H H Norepinephrine Normetanephrine

  8. ADRENERGIC TRANSMISSION Tyrosine TH Tyrosine DOPA DDC Dopamine MAO DA ++ Ca ++ Ca DßH NE NE NE Transp. NE AdR COMT

  9. Drugs that act on adrenergic terminals • Inhibit reuptake of NE into terminal- cocaine, tricyclic antidepressants • Induce release of NE from terminal- amphetamine, tyramine • Inhibit uptake of DA & NE into vesicle- reserpine • Block release of NE- bretylium • Displace NE from vesicle- guanethidine • Inhibit TH activity- a-methyltyrosine • Inhibit DDC activity- carbidopa • Inhibit MAO activity- pargyline • (Inhibit COMT activity- tolcapone)

  10. NE NE Presynaptic Receptors Inhibit NE Release From Terminals NE ß1- AdR NE X X NE a2- AdR NE

  11. The Subtypes of Adrenergic Receptors a: EPI > NOR >>ISO ß: ISO > EPI > NE

  12. Beta- Adrenergic Receptors Mediate Positive Chronotropic Effect 80 Isoproterenol Norepinephrine 60 40 Change in HR. BPM 20 0 Dose, µg/kg 0.1 100 0. 01 0.001 1 10

  13. Even More Subtypes of Adrenergic Receptors a: EPI > NOR >>ISO ß: ISO > EPI > NE a1: contraction of smooth muscle (incl. VSM) a2: presynaptic receptors ( decrease NE release) ß1: in heart and juxtaglomerular cells (and some fat cells) ß2: relaxation of smooth muscle (and in heart) ß3: some fat cells NOTE ON ß2: (1) mediate relaxation of skeletal muscle vasculature (2) P’cologically administered NE is not effective

  14. Specificity of Agonists at Targets and Receptors E NE I Contraction of VSM (a1-AdR) I Relaxation of Airways (ß2-AdR) E NE I E NE Increase in HR (ß1-AdR) Concentration of Drug

  15. Hormone/Transmitter g b a Effector GTP BANG GDP Receptors G-Proteins Effectors 9 adrenergic R 20 a 4 PLC-ß 5 mAChR 5 ß 10 AC 12 g PDE (≥ 100?) K channels (GIRK ) Na, Ca channels IP3 Receptors PI-3-kinases Rho-GEF, Ras-GEF Tyrosine Kinases (src)

  16. Regulator of G-protein Signaling

  17. The basic functions of G-proteins as family: mediates stimulation of adenylyl cyclase (ß-AdR) ai family: mediates inhibition of adenylyl cyclase activates GIRK (M2, M4 mAChR; 2-AdR) aq family: activate certain forms of PLC (M1, M3, M5 mAChR; 1-AdR) (and others as well)

  18. Beta-adrenergic receptors stimulate adenylyl cyclase Norepinephrine Adenylyl Cyclase G-protein ATP (Gs) cAMP cAMP-dependent protein kinase (PKA) Increased phosphorylation

  19. ß- ARR Iso Iso Ad. Ad. g g b Cyc. b a a Cyc. ß- ARR P GRK Regulation of Receptor Signaling by G-protein- Coupled Receptor Kinase (GRK) and ß-Arrestin Receptor is uncoupled from G-protein and targeted for internalization and down-regulation

  20. 40 30 ß-Receptors In Heart 20 10 0 ISO- Treated ISO, Withdrawn Control Chronic Isoproterenol Decreases Cardiac Beta-AdR #

  21. Chronic Isoproterenol Decreases Cardiac Beta-AdR Functional Responsiveness Increase In Contractile Force Control Isoproterenol, Withdrawn (OR) Increase In Adenylyl Cyclase Isoproterenol Treated Concentration of Isoproterenol

  22. 200 150 ß-Receptors In Heart 100 50 0 T3- Treated T4- Treated Control Thyroid Hormones Increase Cardiac Beta-AdR #

  23. Decreased number of cardiac ß-AdR in ventricles of patients with heart failure Controls Heart Failure (Receptor #)

  24. Decreased function of cardiac ß-AdR in ventricles of patients with heart failure

  25. Differential coupling of ß1 and ß2- AdR • ß1-AdR only couple to the stimulatory G-protein Gs • ß2-AdR can couple to both Gs & the inhibitory G-protein Gi • In heart failure, levels of ß1-AdR decrease and levels of Gi increase • Therefore, ß2-AdR has less stimulatory and more inhibitory effects in a failing heart than in a non-failing heart • Failing heart has increased expression and activity of GRK, which increases ß1 desensitization and degradation and also increases coupling of ß2 to Gi • The decreased level of ß1-AdR and increased ß2-AdR coupling to Gi both contribute to decreased ß-adrenergic stimulation of contractility in failing heart

More Related